Research notes
Stay informed with the most recent market and company research insights.

Research Notes
3Q26: On schedule, but funding overhang looms
NexGen Energy
November 14, 2026
Rook I construction progressing on schedule - Following commencement of site works in June, NXG continues to advance engineering, procurement, and site development activities. During the quarter, NXG awarded the shaft sinking contract and commenced shaft preparation works, a key project milestone. >Capex accelerates - 3Q capex rose to C$121m (2Q: C$74m), and NXG expects spend to keep climbing, guiding to C$600m in 2027 as the shaft sinking begins. >We upgrade our rating to BUY (previously ACCUMULATE) with a reduced price target of A$15.15ps (previously A$15.60ps).
Equity Raise: Money in the bank for PLS development
Paladin Energy
November 14, 2026
A$525m equity raising – PDN has completed a A$525m equity raising (with an SPP targeting a further A$50m) that was priced at A$7.80ps. This raise will materially strengthen the balance sheet and remove a key component of funding uncertainty surrounding PLS. >Funding Patterson Lake South (PLS) through critical development milestones - Funds will be directed towards PLS development activities, including detailed engineering, procurement of long-lead items (Tunnel Boring Machine, Gas Turbines etc), underground development and site readiness works, while also supporting resource growth drilling at Triple R and exploration across the Athabasca Basin. >We maintain our BUY rating with a reduced price target of A$11.25ps (previously A$13.10ps).
FY26 the trough; FY27 recovery underway but below TTC
GrainCorp
November 14, 2026
GNC’s FY26 result was in line with its September guidance update. Earnings declined materially due to lower volumes and weak grain trading margins. Operating cashflow was weak. >As usual, GNC didn’t provide FY27 guidance (due at the February 2027 AGM). A well above average 2026/27 east coast crop, improving export and crush margins and the full benefit of A$12m of Business Transformation savings all bode well for higher earnings in FY27. However, earnings are likely to be below GNC’s ‘through-the-cycle’ (TTC) EBITDA guidance. >Our NPAT forecasts have fallen 10-12% due to higher interest expense. Following the recent share price strength, we move to a HOLD rating (from ACCUMULATE) with a new A$7.75 price target.
Stepping back
Accent Group
November 13, 2026
AX1 has provided a weak trading update for the first 19 weeks of FY27. Sales have moderated in the last 12 weeks, with spending in the footwear category impacted by a softening consumer environment driven by elevated fuel prices, interest rate increases and weak consumer confidence. >Gross cost savings of $30m have been implemented for FY27, but given the weaker trading conditions we no longer expect a $10-15m net benefit to eventuate. >We have lowered our EBIT forecasts by ~6% in FY27/28 and reduced our price target to $0.68 (from $0.77). Our target sits only marginally above the $0.65 Frasers offer. Whilst we do think the share price undervalues the longer-term potential of the business, we see limited reason for the stock to re-rate in the near term. We move to a HOLD (from an ACCUMULATE).
October performance to weigh on fees and flows
Regal Partners
November 13, 2026
RPL has advised that CY26 fund performance fee revenue will be at least $122.7m (Consensus was at $168.9m), with no further material performance fees expected in 2H26 beyond the amount already received (1H26 $118.7m, plus $4.0m for July to October). This is around $46m below consensus and around $74m below our prior $196.6m forecast, and follows a sharp drawdown across Regal's hedge fund strategies in October (Figure 2). Management also expects Other Income to have no material impact on CY26 Normalised NPAT, reflecting the weak share price of Regal Asian Investments (ASX:RG8). >Net flows remain resilient, with $2.2bn of net inflows in the ten months to October (a 12th consecutive positive quarter) and FUM of around $22bn. >We cut CY26 Normalised NPAT by around 35% to $99.8m (EPS 22.8cps), trim CY27 and CY28 by around 10% and 5%, and lower our price target to A$4.00 (from A$4.25). With the recurring fee base intact, we retain our BUY recommendation; the key near-term risk is that soft performance pressures flows and amplifies the uncertainty around Phil King's planned retirement.
Philips partnership has big potential
Imricor Medical Systems
November 13, 2026
The regulatory clearance for atrial flutter (AF) is progressing with approval expected 1Q27. >At this stage revenues are modest. We look forward to an acceleration of revenue quarter over quarter particularly once the AF approval is received. Also, the Philips partnership has the potential to unlock significant revenue growth as the installed base and Philips sales team are unlocked. >We have made no changes to forecasts or target price (A$2.90). Our SPECULATIVE BUY recommendation is maintained.
Blasting ahead, with interest
Orica
November 12, 2026
Despite a number of external challenges, ORI’s FY26 result slightly beat consensus estimates. Underlying EBIT rose 6.5% (+11% in constant currency) and NPAT increased 9.0%. Digital Solutions and Specialty Mining Chemicals (both +25% EBIT) drove the growth. Pleasingly, operating cashflow was also better than expected and the balance sheet is strong. >In FY27, ORI expects earnings growth from all three segments. Plant turnarounds and materially higher interest costs (+A$25-35m) mean modest NPAT growth. Growth should accelerate in FY28. We have made minor revisions to our forecasts. >We maintain an ACCUMULATE rating with a revised price target of A$26.98.
A strong start, a conservative 2H
Wagners
November 12, 2026
A positive AGM update. FY27 Operating EBIT guidance of $72m to $76m (+7% to +13%) brackets Consensus ($72.8m). 1H27 guidance of $40m to $42m was the standout, with the $41.0m midpoint 12% ahead of Consensus. The implied 2H27 (~$33m, 10% below Consensus) appears to reflect the full quantified cost and seasonality headwinds, with no credit for pricing, new capacity or the potential PNG LNG project (US$50m to US$55m, FID mid-December). We see risk skewed to the upside. >We lift FY27F/FY28F Operating EBIT by 3.5%/2% to $75.4m/$85.3m, in the upper half of guidance. Our target price rises to $5.90 (from $5.25) on a higher applied multiple. Buy rating retained.
Hitting restart on the rule of 40
Xero
November 12, 2026
XRO’s 1H27 result was broadly in line with expectations and comes with a small upgrade to FY27 guidance (including now expecting to hit Rule of 40 in FY27). >Shares have underperformed by ~50% over the past 12 months. The guidance upgrade, improving US/Melio traction, better articulation of XRO’s positioning in the context of AI and a newly announced A$1bn on-market buy-back are all positive news and, in our view, should be well received by investors. >We lift our Target Price to A$90 and retain our ACCUMULATE recommendation.
Momentum continues to build
Acrow
November 12, 2026
ACF provided a positive trading update with FY27 underlying EBITDA upgraded by ~5% at the mid-point. >The upgrade reflected a strong start to the financial year in both the Industrial Access and Construction segments. Pleasingly, management said the recent acquisitions of SuperDeck and AGIS are performing to expectations. >We increase FY27-29F underlying EBITDA by 6%. >Our target price rises to $1.45 (from $1.40) and we maintain our BUY rating. We remain positive on ACF following another upgrade to FY27 earnings guidance. Momentum continues to build across both the Industrial Access and Construction segments with a strong growth outlook over the medium term supported by increasing activity in QLD (including commercial, infrastructure and Brisbane Olympics), the Sydney Harbour Bridge refurbishment, and Snowy 2.0. Trading on 9.6x FY27F PE with a yield of 3.4%, we see the stock as undervalued relative to its growth outlook (3-year underlying EPS CAGR of 20%).
News & insights
November 12, 2026
November 12, 2026
min read
Financial services internship: what one QUT student learned at Morgans
Morgans Opinion
Opinion
November 11, 2026
November 10, 2026
min read
Macro Monthly Market: A Worldly Lens - October 2026
Scott Fraser (AR: 001254347)
Financial Adviser
November 9, 2026
November 6, 2026
min read
How does inflation affect house prices in Australia? What to know
Ken Howard (AR: 000259290)
Private Client Adviser


